All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
IO-202 (anti-LILRB4) receives FDA orphan drug designation for the treatment of R/R AML
By Sumayya Khan
Bookmark this article
On November 10, 2020, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to IO-202 for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). IO-202 is a first-in-class monoclonal antibody that blocks the signaling of the immune inhibitory receptor LILRB4, thus activating T-cell cytotoxicity against leukemia cells.1
IO-202 is currently being investigated in a multicenter, open-label, phase I dose escalation and expansion study (NCT04372433), which was previously described on the AML Hub when reporting on the FDA clearance of IO-202 for investigation as a new drug in AML and chronic myelomonocytic leukemia. The novel mechanism of action of IO-202 and this ongoing trial are due to be presented as a trial-in-progress poster at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, in December.1
- Immune-Onc Therapeutics. Immune-Onc Therapeutics announces orphan drug designation of IO-202 (anti-LILRB4) for treatment of AML and poster presentation at ASH 2020. https://www.immune-onc.com/news/2020-11-10-io-202-odd-ash. Published Nov 10, 2020. Accessed Nov 11, 2020.
More about...
Your opinion matters
29 votes - 44 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox